Directori de persones
Antonio Garcia Guiñon

Antonio Garcia Guiñon

Grau: Llicenciat/da

973 705351
agarciag.lleida.ics(ELIMINAR)@gencat.cat

Publicacions

  • González-Guerrero, L; Castellet, H; Martínez, C; González, N; Guijarro, F; Lloveras, N; Pratcorona, M; Gich, I; Berenguer-Molins, P; Perera-Bel, J; Zamora, L; Mascaró, M; Sampol, A; Garcia-Guiñón, A; Vives, S; Tormo, M; Arnan, M; Villamor, N; Nomdedéu, JF

    CD200 in acute myeloid leukemia: marked upregulation in CEBPA biallelic mutated cases

    Diagnostic Pathology 20 56-56. .

    [doi:10.1186/s13000-025-01655-w]

  • Garcia-Guiñon, A; Charry, PA; Jimenez, M; Sarra, J; Delgado, I; de la Torre, LS; Santaliestra, M; Garcia-Pintos, M; Gonzalez, Y; Senin, A; Motlló, C; Abella, E; Cabezudo, E; Granell, M; Sancho, E; Herranz, MJ; Seres, Y; Gironella, M; Soler, JA; Marti-Tutusaus, JM; Ben Azaiz, R; de Larrea, CF

    Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma

    ANNALS OF HEMATOLOGY 104 1177-1186. .

    [doi:10.1007/s00277-025-06240-1]

  • Oñate G; Garrido A; Arnan M; Pomares H; Alonso E; Tormo M; Diaz-Beya M; Vives S; Zamora L; Sampol A; Coll R; Salamero O; Cervera M; Garcia A; Vall-Llovera F; Garcia-Avila S; Bargay J; Ortin X; Iranzo E; Guijarro F; Pratcorona M; Nomdedeu JF; Esteve J; Sierra J

    Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

    Blood Cancer Journal 15 4-4. .

    [doi:10.1038/s41408-024-01205-5]

  • Ribera JM; Morgades M; Garcia-Calduch O; Sirvent M; Buendia B; Cervera M; Luzardo H; Hernandez-Rivas JM; Sitges M; Garcia-Cadenas I; Abrisqueta P; Montesinos P; Bastos-Oreiro M; De Llano MQ; Bravo P; Torrent A; Herrera P; Garcia-Guinon A; Vall-Llovera F; Serrano J; Terol MJ; Bergua JM; Garcia-Noblejas A; Barrenetxea C; Llorente L; Garcia-Belmonte D; Gimeno E; Cladera A; Mercadal S; Sancho JM

    Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL 109 543-552. .

    [doi:10.3324/haematol.2023.283342]

  • Oñate G; Pratcorona, M; Garrido, A; Artigas-Baleri, A; Bataller, A; Tormo, M; Arnan, M; Vives, S; Coll, R; Salamero, O; Vall-Llovera, F; Sampol, A; Garcia, A; Cervera, M; Avila, SG; Bargay, J; Ortin, X; Nomdedeu, JF; Esteve, J; Sierra, J

    Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.

    Blood Cancer Journal 13 69-69. .

    [doi:10.1038/s41408-023-00839-1]

  • Diaz-Santa, J; Rodriguez-Romanos, R; Coll, R; Osca, G; Pratcorona, M; Gonzalez-Bartulos, M; Garrido, A; Angona, A; Talarn, C; Tormo, M; Arnan, M; Vives, S; Salamero, O; Tuset, E; Lloveras, N; Diez, I; Zamora, L; Bargay, J; Sampol, A; Cruz, D; Vila, J; Sitges, M; Garcia, A; Vall-Llovera, F; Esteve, J; Sierra, J; Gallardo, D

    5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

    EUROPEAN JOURNAL OF HAEMATOLOGY 109 755-764. .

    [doi:10.1111/ejh.13862]

  • Gonzalez J; Jatem E; Roig J; Valtierra N; Ostos E; Abo A; Santacana M; Garcia A; Segarra A

    Usefulness of urinary biomarkers to estimate the interstitial fibrosis surface in diabetic nephropathy with normal kidney function.

    NEPHROLOGY DIALYSIS TRANSPLANTATION 37 2102-2110. .

    [doi:10.1093/ndt/gfac185]

  • Moreno, DF; Clapés, V; Soler, JA; González-Montes, Y; Gironella, M; Motlló, C; Granell, M; Abella, E; García-Pintos, M; García-Guiñón, A; Cabezudo, E; Bladé, J; Rosiñol, L

    Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas

    Clinical Lymphoma Myeloma & Leukemia 22 635-642. .

    [doi:10.1016/j.clml.2022.04.014]

  • Encinas, C; Hernandez-Rivas, JA; Oriol, A; Rosinol, L; Blanchard, MJ; Bellon, JM; Garcia-Sanz, R; de la Rubia, J; de la Guia, AL; Jimenez-Ubieto, A; Jarque, I; Inigo, B; Dourdil, V; de Arriba, F; Perez-Avila, CC; Gonzalez, Y; Hernandez, MT; Bargay, J; Granell, M; Rodriguez-Otero, P; Silvent, M; Cabrera, C; Rios, R; Alegre, A; Gironella, M; Gonzalez, MS; Sureda, A; Sampol, A; Ocio, EM; Krsnik, I; Garcia, A; Garcia-Mateo, A; Soler, JA; Martin, J; Arguinano, JM; Mateos, MV; Blade, J; San-Miguel, JF; Lahuerta, JJ; Martinez-Lopez, J

    A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood Cancer Journal 12 -. .

    [doi:10.1038/s41408-022-00652-2]

  • Bataller, A; Garrido, A; Guijarro, F; Oñate G; Diaz-Beya, M; Arnan, M; Tormo, M; Vives, S; de Llano MPQ; Coll, R; Gallardo, D; Vall-Llovera, F; Escoda, L; Garcia-Guinon, A; Salamero, O; Sampol, A; Merchan, BM; Bargay, J; Castaño-Díez S; Esteban, D; Oliver-Caldes, A; Rivero, A; Mozas, P; Lopez-Guerra, M; Pratcorona, M; Zamora, L; Costa, D; Rozman, M; Nomdedeu, JF; Colomer, D; Brunet, S; Sierra, J; Esteve, J

    European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.

    Blood Advances 6 1193-1206. .

    [doi:10.1182/bloodadvances.2021005585]

  • Onate, G; Bataller, A; Garrido, A; Hoyos, M; Arnan, M; Vives, S; Coll, R; Tormo, M; Sampol, A; Escoda, L; Salamero, O; Garcia, A; Bargay, J; Aljarilla, A; Nomdedeu, JF; Esteve, J; Sierra, J; Pratcorona, M

    Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

    Blood Advances 6 882-890. .

    [doi:10.1182/bloodadvances.2020004136]

  • Villalba, A; Gonzalez-Rodriguez, AP; Arzuaga-Mendez, J; Puig, N; Arnao, M; Arguinano, JM; Jimenez, M; Canet, M; Teruel, AI; Sola, M; Diaz, FJ; Encinas, C; Garcia, A; Rosinol, L; Suarez, A; Gonzalez, MS; Izquierdo, I; Hernandez, MT; Infante, MS; Sanchez, MJ; Sampol, A; de la Rubia, J

    Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

    LEUKEMIA & LYMPHOMA 63 3438-3447. .

    [doi:10.1080/10428194.2022.2123229]